Companies in #Inflammatory Disease
Found 3 companies operating in this sector.
Beijing-headquartered global biotechnology company (SSE: 688796, HKEX: 02315) providing integrated antibody drug development solutions through proprietary gene-editing platforms and RenMab/RenNano antibody discovery engines.
Shattuck Labs is a clinical-stage biotechnology company developing novel biotherapeutics based on its proprietary Agonist Redirected Checkpoint (ARC) platform, which combines elements of antibody and cytokine receptor signaling in single fusion proteins for the treatment of cancer and inflammatory disease.
Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of STAT3 inhibitors for cancer and inflammatory diseases. The company's lead candidate TTI-101 is an oral small-molecule STAT3 inhibitor; TTI-109 is a phosphate prodrug of TTI-101 designed to improve oral bioavailability while preserving target engagement. The Phase 1 study of TTI-109 announced July 7, 2026 confirmed rapid prodrug conversion to TTI-101 within two hours, dose-proportional pharmacokinetics with plasma levels above the STAT3 IC50, and reductions of up to 60% in STAT3-driven immune cell populations across Th17, Tfh, and B cell subsets in an exploratory pharmacodynamic analysis. Planned Phase 2 initiation in hepatocellular carcinoma and other STAT3-driven indications is the next value-driving event. Tvardi is headquartered in Houston, Texas and trades on the Nasdaq Capital Market under the symbol TVRD.